Utilizing the prioritized ilQTLs, we establish a polygenic risk score (PRS) that proves more accurate in predicting response to checkpoint inhibition in melanoma and gastric cancer patients than PD-L1 expression, providing direct support of the potential utility of UTR variants in predictive modeling in immunotherapy. The gene discussed is CD274; the disease is gastric cancer.